Onkure Therapeutics Inc
OKUR3.000USD
-0.100-3.23%
收盤 11/05, 16:00（美東）報價延遲15分鐘
40.59M總市值
虧損本益比TTM
關於 Onkure Therapeutics Inc 公司
OnKure Therapeutics, Inc.（前身爲 Reneo Pharmaceuticals, Inc.）是一家臨牀階段的生物製藥公司，專注於發現和開發精準藥物，這些藥物針對的是現有療法無法滿足的、經過生物學驗證的癌症驅動因素。該公司正在利用基於結構的藥物設計平臺，建立一個強大的腫瘤無關候選藥物產品線。該公司正在開發選擇性 PI3KαH1047R 抑制劑 OKI-219 作爲其主要項目。OKI-219 正在針對 PI3KαH1047R 突變的實體瘤患者（包括乳腺癌）進行 I 期臨牀試驗評估。該公司還專注於靶向致癌 PI3Kα，並有多個旨在靶向這一關鍵致癌基因的項目。
Onkure Therapeutics Inc簡介
公司代碼OKUR
公司名稱Onkure Therapeutics Inc
上市日期Apr 09, 2021
CEODr. Nicholas A. Saccomano, Ph.D.
員工數量46
證券類型Ordinary Share
年結日Apr 09
公司地址6707 Winchester Circle, Suite 400
城市BOULDER
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編80301
電話17203072892
網址https://onkuretherapeutics.com/
公司代碼OKUR
上市日期Apr 09, 2021
CEODr. Nicholas A. Saccomano, Ph.D.
Onkure Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
15.32K
+56.70%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dylan Hartley, Ph.D.
Dr. Dylan Hartley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ed T. Mathers ,
Ed T. Mathers ,
Independent Director
Independent Director
--
--
Ms. Valerie M. Jansen, M.D., Ph.D.
Ms. Valerie M. Jansen, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Michael Carruthers
Mr. R. Michael Carruthers
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
15.32K
+56.70%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Acorn Capital Advisors, LLC
22.11%
Citadel Advisors LLC
8.48%
Shay Capital LLC
6.09%
The Vanguard Group, Inc.
5.50%
Cantor Fitzgerald, L.P
5.21%
其他
52.60%
持股股東
持股股東
佔比
Acorn Capital Advisors, LLC
22.11%
Citadel Advisors LLC
8.48%
Shay Capital LLC
6.09%
The Vanguard Group, Inc.
5.50%
Cantor Fitzgerald, L.P
5.21%
其他
52.60%
股東類型
持股股東
佔比
Investment Advisor
34.22%
Hedge Fund
24.32%
Investment Advisor/Hedge Fund
15.32%
Venture Capital
9.02%
Private Equity
3.83%
Individual Investor
1.73%
Research Firm
0.32%
其他
11.25%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
177
11.18M
87.02%
-5.50M
2025Q2
186
12.83M
100.04%
-1.08M
2025Q1
187
12.71M
99.28%
-1.05M
2024Q4
190
12.64M
105.50%
+4.22M
2024Q3
172
2.79M
546.32%
-1.40M
2024Q2
171
3.11M
93.03%
-1.12M
2024Q1
161
3.05M
91.28%
-864.58K
2023Q4
152
2.81M
85.98%
-309.72K
2023Q3
128
3.01M
91.00%
-83.83K
2023Q2
119
2.90M
88.58%
+621.98K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Acorn Capital Advisors, LLC
2.84M
22.11%
--
--
Jun 30, 2025
Citadel Advisors LLC
1.09M
8.48%
+21.21K
+1.99%
Jun 30, 2025
Shay Capital LLC
782.05K
6.09%
-28.17K
-3.48%
Jun 30, 2025
The Vanguard Group, Inc.
706.73K
5.5%
--
--
Jun 30, 2025
Cantor Fitzgerald, L.P
669.54K
5.21%
+538.84K
+412.27%
Jun 30, 2025
Highbridge Capital Management, LLC
663.61K
5.17%
+224.81K
+51.23%
Jun 30, 2025
Vestal Point Capital, LP
635.00K
4.94%
--
--
Jun 30, 2025
StepStone Group LP
491.94K
3.83%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
478.55K
3.73%
--
--
Jun 30, 2025
BlackRock Financial Management, Inc.
463.59K
3.61%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
ALPS Medical Breakthroughs ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0%
iShares Russell 2000 ETF
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
ALPS Medical Breakthroughs ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
Global X Russell 2000 Covered Call ETF
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
Global X Russell 2000 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
公告日期
類型
比率
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
